Committee favors EU approval of Qalsody for adults with SOD1-ALS
An advisory committee of the European Medicines Agency (EMA) has recommended that Biogen’s Qalsody (tofersen) be approved in the…
Articles by Andrea Lobo, PhD
Phase 1 trial testing prosetin for ALS expands to EU countries
ProJenX has been given the green light to expand its ongoing Phase 1 clinical trial of prosetin for amyotrophic…
TPN-101 improves ALS/FTD caused by C9orf72 gene mutations
TPN-101, an investigational oral molecule developed by Transposon Therapeutics, reduced multiple biomarkers of neuroinflammation and neurodegeneration, and slowed respiratory…
$400K ALS Association grant will advance CSF-1R inhibitor program
Myrobalan Therapeutics will use a $400,000 grant from the ALS Association — along with $24 million in new…
$20K gift supports Ball State work into C9orf72-linked ALS
A research team at Ball State University has received a $20,000 donation from the Todd Siebert Memorial Foundation…
Phase 2 trial of oral IFB-088 for bulbar-onset ALS now fully enrolled
Enrollment is complete in a Phase 2 trial testing InFlectis BioScience’s oral candidate IFB-088 (icerguastat) in people with…
Trial of cell-based therapy CK08031 finishes dosing 1st patient group
An early-stage clinical trial evaluating CK0803, Cellenkos‘ regulatory T-cell-based therapy for people with amyotrophic lateral sclerosis (ALS), has…
Verge launches Phase 1 trial to test PIKfyve inhibitor therapy in ALS
Verge Genomics has launched a proof-of-concept trial to test whether VRG50635, its oral PIKfyve inhibitor therapy, can be used…
Coya aligns with FDA on plans for developing COYA 302 for ALS
After two meetings with the U.S. Food and Drug Administration (FDA), Coya Therapeutics says it’s received constructive feedback —…
Arbor, 4DMT to develop novel gene therapies for ALS, other diseases
Arbor Biotechnologies and 4DMT — two U.S. companies working in next-generation genetic medicines — have established a strategic…